Christopher Zosh - Statera Biopharma Interim Fin
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Insider
Christopher Zosh is Interim Fin of Statera Biopharma
| Age | 47 |
| Phone | 888 613 8802 |
| Web | https://www.staterabiopharma.com |
Statera Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.2385) % which means that it has lost $0.2385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8694) %, meaning that it created substantial loss on money invested by shareholders. Statera Biopharma's management efficiency ratios could be used to measure how well Statera Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Shiran Zimri | NeuroSense Therapeutics Ltd | N/A | |
| Avital Pushett | NeuroSense Therapeutics Ltd | N/A | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Clare MBA | Alector | N/A | |
| Erica Jefferson | Alector | N/A | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Marc MD | Alector | 50 | |
| Michelle Corral | Alector | N/A | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Marcy Graham | Aadi Bioscience | 57 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Ferenc Tracik | NeuroSense Therapeutics Ltd | 60 | |
| Or Eisenberg | NeuroSense Therapeutics Ltd | 43 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Brendan MBA | Aadi Bioscience | 49 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
Management Performance
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 |
Statera Biopharma Leadership Team
Elected by the shareholders, the Statera Biopharma's board of directors comprises two types of representatives: Statera Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Statera. The board's role is to monitor Statera Biopharma's management team and ensure that shareholders' interests are well served. Statera Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Statera Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Wagner, Ex Affairs | ||
| Dr Buckheit, Chief Officer | ||
| Christopher Zosh, Interim Fin | ||
| Todd Headley, Exec Devel | ||
| Michael Handley, Pres CEO |
Statera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Statera Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Shares Owned By Insiders | 15.93 % | ||||
| Shares Owned By Institutions | 5.41 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |